Bacillus calmette-guerin substrain connaught live antigen

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Bacillus calmette-guerin substrain connaught live antigen
Accession Number
DB10804
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Attenuated
Description

Bacillus calmette-guerin substrain connaught live antigen is intravesically administered for the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR). The solution contains live, attenuated strain of Mycobacterium bovis. It is prepared from the Connaught strain of Bacillus Calmette and Guérin.

Synonyms
  • BCG, Live, Connaught Strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TheracysInjection, powder, lyophilized, for solution81 mg/3mLIntravesicalSanofi Pasteur Limited2011-07-222017-05-08Us
Categories
UNII
5H5854UBMZ
CAS number
Not Available

Pharmacology

Indication

Indicated for intravesical use in the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR).

Associated Conditions
Associated Therapies
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with 2-Methoxyethanol.
2-MethoxyethanolThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with 2-Methoxyethanol.
6-Deoxyerythronolide BThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
9-(N-methyl-L-isoleucine)-cyclosporin AThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abatacept.
AbataceptThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abatacept.
AbetimusThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Abetimus.
AbetimusThe risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Acetyl sulfisoxazole.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910910
AHFS Codes
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3Not Yet RecruitingTreatmentBladder Cancers1
3RecruitingTreatmentBladder Cancers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravesical81 mg/3mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on December 01, 2015 13:04 / Updated on January 22, 2019 17:57